MetLife Investment Management, LLC - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 173 filers reported holding DENALI THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 1.34 and the average weighting 0.6%.

Quarter-by-quarter ownership
MetLife Investment Management, LLC ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,284,506
-30.1%
62,2640.0%0.01%
-28.6%
Q2 2023$1,837,411
+39.8%
62,264
+9.2%
0.01%
+40.0%
Q1 2023$1,313,902
-17.2%
57,0270.0%0.01%
-23.1%
Q4 2022$1,585,921
-1.4%
57,027
+8.8%
0.01%
-7.1%
Q3 2022$1,608,985
+8.5%
52,427
+4.0%
0.01%
+16.7%
Q2 2022$1,483,037
-8.5%
50,3920.0%0.01%
+9.1%
Q1 2022$1,621,111
+12.2%
50,392
+55.6%
0.01%
-8.3%
Q4 2021$1,444,549
-11.6%
32,3890.0%0.01%
-20.0%
Q3 2021$1,634,025
-35.7%
32,3890.0%0.02%
-37.5%
Q2 2021$2,540,593
+79.7%
32,389
+30.8%
0.02%
+84.6%
Q1 2021$1,414,024
-31.8%
24,7640.0%0.01%
-38.1%
Q4 2020$2,074,233
+105.9%
24,764
-11.9%
0.02%
+90.9%
Q3 2020$1,007,253
+48.2%
28,1120.0%0.01%
+37.5%
Q2 2020$679,748
+71.1%
28,112
+23.9%
0.01%
+33.3%
Q1 2020$397,302
+9.0%
22,690
+8.5%
0.01%
+50.0%
Q4 2019$364,339
+13.7%
20,9150.0%0.00%0.0%
Q3 2019$320,418
-26.2%
20,9150.0%0.00%
-20.0%
Q2 2019$434,195
-10.6%
20,9150.0%0.01%0.0%
Q1 2019$485,646
+12.4%
20,9150.0%0.01%0.0%
Q4 2018$432,104
-5.0%
20,9150.0%0.01%0.0%
Q3 2018$454,692
+84.8%
20,915
+67.7%
0.01%
+66.7%
Q1 2018$246,00012,4690.00%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q3 2020
NameSharesValueWeighting ↓
Crestline Management, LP 7,460,732$240,012,00028.78%
Casdin Capital, LLC 1,500,000$48,255,0002.16%
Flagship Pioneering Inc. 2,619,968$84,284,0001.98%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 38,000$8,192,0001.85%
Yiheng Capital Management, L.P. 1,014,684$32,642,0001.49%
SECTORAL ASSET MANAGEMENT INC 207,100$6,662,0001.18%
Artal Group S.A. 600,000$19,302,0000.81%
GILDER GAGNON HOWE & CO LLC 2,619,217$84,260,0000.78%
Temasek Holdings (Private) Ltd 5,369,487$172,736,3970.73%
BRANDYWINE MANAGERS, LLC 9,601$309,0000.53%
View complete list of DENALI THERAPEUTICS INC shareholders